Screener
Edgewise Therapeutics, Inc. EWTX Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development | $42,651 | $36,757 |
| General and administrative | 11,464 | 9,202 |
| Total operating expenses | 54,115 | 45,959 |
| Loss from operations | (54,115) | (45,959) |
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
| Net loss | (49,013) | (40,798) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s operating income?
- Edgewise Therapeutics, Inc. (EWTX) reported operating income of -$54.12M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s operating income changed year-over-year?
- Edgewise Therapeutics, Inc.'s operating income decreased by 17.7% year-over-year, from -$45.96M to -$54.12M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s operating income has grown at a 45.1% compound annual growth rate (CAGR), from -$43.22M to -$191.41M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Edgewise Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude